WHO ICTRP trial
LETITIA; LutEtium doTatate consolIdaTion In Aggressive meningioma
CTRI/2026/01/100666 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2026/01/100666 |
|---|---|
| Public title | LETITIA; LutEtium doTatate consolIdaTion In Aggressive meningioma |
| Scientific title | LutEtium doTatate consolIdaTion In Aggressive meningioma (LETITIA) - A Phase II study - LETITIA |
| Primary sponsor | Tata Research and Administrative Council(TRAC) |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | India |
| Conditions | Health Condition 1: D496- Neoplasm of unspecified behavior of brain |
| Interventions | Intervention1: Lutetium (177Lu) DOTATATE: The intervention consists of a maximum of four sessions of Lutetium-177 (Lu-177) DOTATATE Peptide Receptor Radionuclide Therapy (PRRT), with each session spaced 6 8 weeks apart. Patients receive an… |
| Registration date | Sep 1, 2026 |
| Target size | 28 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: